TP53 and thyroid gland carcinoma: Of the thyroid cancers, p53 inactivation is particularly common in PDTCs and ATCs, with a prevalence of 8–35% in PDTCs and significantly higher prevalence of up to 73% in ATCs, especially in association with BRAFV600E mutation [17,19,20].